

## Who we are



*We are a science-led global healthcare company with a special purpose: to help people do more, feel better and live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.*

## What we do



*We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible with our three global businesses, scientific and technical know-how and talented people.*

## How we do it



*Everyone at GSK is focused on 3 priorities – Innovation, Performance, Trust*

***Innovation:*** *We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.*

***Performance:*** *We aim to achieve industry-leading growth by investing effectively in our business, developing our people and delivering flawlessly.*

***Trust:*** *We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer.*

***Our values and expectations*** *are at the heart of everything we do and help define our culture – so that together we can deliver extraordinary things for our patients and consumers and make GSK a brilliant place to work.*

# GSK in Canada Fast Facts

**Heritage** GSK's history in Canada dates back to 1902

**Employees** Employs approx. 2,000 full time employees across the country, providing a salary injection of \$225 million into the Canadian economy.



**Locations** Two divisional headquarters in Mississauga, Ontario and Laval, Quebec, and an administrative office in Quebec City.

**Manufacturing** Two manufacturing facilities



1. Mississauga (Ontario) manufacturing site produces approximately 50 different products, exporting 90% to more than 100 markets worldwide.
2. Ste-Foy (Quebec) vaccine manufacturing site currently produces a majority share of Canada's seasonal influenza vaccine and is responsible for the domestic supply of the country's pandemic influenza vaccine requirements.

**Research & Development** Invested more than \$2 billion since 2001 in Canadian pharmaceutical and vaccines R&D, ranking GSK among the top 10 contributors to R&D in Canada across all industries.



In 2017 alone, GSK in Canada invested over \$65 million to R&D.

Helped establish 22 Research Chairs in Faculties of Medicine and Pharmacy at Canadian universities in respiratory healthcare, vaccinology, HIV, oncology, and management of chronic disease amongst others.

In 2017, invested \$ 13.2 million into 31 active clinical trials across Canada involving 1,921 active subjects.

Supported 17 Investigator Sponsored Studies with physicians across Canada in 2017.

In 2017, sponsored approx. 30 Canadian research projects, focused on health economics and outcomes research to support the scientific understanding of our medicines and vaccines.

**Product Portfolio**



Helping to transform the treatment of asthma, COPD and other respiratory diseases, we have a full, broad and innovative respiratory portfolio spanning established and new compounds and delivery systems.



We have a comprehensive vaccines portfolio, helping to protect children, teenagers, adults & elderly and travellers against diseases like whooping cough, hepatitis, meningitis and shingles.



Spanning across five categories (pain relief, respiratory, digestive health, oral health, nutrition and skin health), we produce consumer healthcare brands including VOLTAREN, NEOCITRAN, TUMS, SENSODYNE, and BUCKLEY'S.

**Community Investment**



An Imagine Canada Caring Company since 1990, GSK contributes over 1% of pre-tax profits annually to initiatives in health and local community organizations.

A contributor to Health Partners International of Canada (HPIC) since 1994, we have provided \$30 million worth of product donations and over \$1 million in grants for the provision of medical relief to vulnerable communities globally. In 2017, our support of HPIC's Humanitarian Medical Kit program contributed to the delivery of over 1.6 million treatments of vital medicines to people in need.

Proud partner with the Canadian Hospice Palliative Care Association (CHPCA) for more than 20 years, contributing over \$2 million to support the hospice palliative care movement in Canada.

Initiated in 2013, GSK's partnership with Save the Children aims to help save one million children's lives. Employees from around the world have raised an impressive £3.1 million (approx. \$5.5 million CDN), which is matched by GSK. In 2017, Canadian employees contributed over \$85,000 to Save the Children.

GSK and Save the Children Canada are supporting Indigenous children, families and communities to prepare for climate-related disasters. Since 2016, 2,200 emergency backpacks have been delivered to children in Ontario and Manitoba.

**Ways of Working**



Among a group of 10 Innovative Medicines Canada members who have voluntarily agreed to publicly report aggregate payments made to healthcare professionals and healthcare organizations. Disclosure of 2017 payments were made in June 2018.

**Environmental Sustainability**



Completed in 2012, GSK's administrative building in Laval, Quebec received Leadership in Energy and Environmental Design (LEED) Gold certification from the Canada Green Building Council. GSK Canada supports the Medications Return Program at pharmacies throughout the country.

GSK supports provincial stewardship associations across the country to ensure our packaging components can be recycled through Local Blue Box programs.

Completed in 2012, GSK's administrative building in Laval, Quebec received leadership in Energy and Environmental Design (LEED) Gold certification from the Canada Green Building Council.

Raised the set building temperature at GSK's Mississauga head office 1.5 degrees during the summer months, reducing demand on the utility grid and resulting in savings of 102,000 kWh. This is equivalent to reducing greenhouse gas emissions of 15 cars for a year.

Through 2017, converted conventional bulbs with LED bulbs, which can consume up to 40% less energy than fluorescent light and over 90% less than traditional incandescent light bulbs.